INDP
Indaptus Therapeutics IncKey Statistics
About Indaptus Therapeutics Inc
Indaptus Therapeutics Inc. is a cutting-edge biotechnology firm focused on pioneering immunotherapies that aim to transform the landscape of cancer treatment. Utilizing a proprietary platform that enhances the immune system's capacity to identify and destroy tumor cells, the company is dedicated to increasing treatment efficacy and improving patient outcomes. With a robust portfolio of clinical candidates addressing critical unmet medical needs within oncology, Indaptus is strategically positioned for growth in an increasingly competitive market. Its dedication to scientific innovation and partnerships with leading research institutions highlights its potential as a transformative force in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.83M |
| Operating Margin | 0.00% |
| Return on Equity | -588.00% |
| Return on Assets | -148.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.45 |
| Price-to-Book | 2.01 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.24M |
| Float | $1.18M |
| % Insiders | 37.17% |
| % Institutions | 1.85% |
Historical Volatility
Volatility is currently contracting